CLINICAL TRIAL EVIDENCE FOR GLP-1 RAs IN MASH Table 2 provides a summary of phase 2 and phase 3 studies examining GLP-1 RAs and dual or triple agonists (aiming glucagon, GIP, and GLP-1 receptors) in individuals with MASLD/MASH, where hepatic biopsies were used to evaluate liver outcomes [3,5,10,11,15,22-25,44-52]
REDOX imbalance is emerging as an important, underappreciated mechanism across neurodevelopmental, neuropsychiatric, and neurological conditions
Los cidos grasos de cadena corta producidos por la fermentacin bacteriana de la fibra pueden estimular la secrecin de GLP-1, aunque esta relacin es compleja y sigue siendo objeto de investigacin en humanos
Tracking data from clinical participants showed those consistently hitting 70+ ounces of water daily experienced zero serious complications
Gut microbiome and kidney stone disease: not just an Oxalobacter story